BDX-XL2

Summary of Evidence Analysis of Evidence General Information Associated Information Sources of Information Bibliography Revision History Information Associated Documents Attachments Related Local Coverage Documents Related National Coverage Documents Public Versions Keywords Local Coverage Determination (LCD) BDX-XL2 L37031 Expand All | Collapse All  Email Document  Download  Add to basket Contractor Information Contractor Name Contract Type Contract Number Jurisdiction States LCD Information Document Information LCD ID L37031 LCD Title BDX-XL2 Proposed LCD in Comment Period N/A Source Proposed LCD DL37031 Original Effective Date For services performed on or after 07/10/2017 Revision Effective Date For services performed on or after 04/28/2022 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 05/25/2017 Notice Period End Date 07/09/2017 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the A

This Medicare contractor will provide limited coverage for the BDX-XL2 test (Biodesix, Seattle, WA) for the management of a lung nodule, between 8 and 30mm in diameter, in patients 40 years or older and with a pre-test cancer risk (as assessed by the Mayo Clinic Model for Solitary Pulmonary Nodules) of 50% or less. The intended use of the test is to assist physicians in the management of lung nodules by identifying those lung nodules with a high probability of being benign. These lung nodules would then be candidates for non-invasive computed tomography (CT) surveillance instead of invasive procedures.